Skip to main content

Table 2 Summarized effect estimates of univariable Cox regression in discovery and validation analysis

From: Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts

 

Disease-free survival

    

Overall survival

     

Recurrence

    
 

Discovery

  

Validation

  

Discovery

  

Validation

  

Discovery

  

Validation

  

Risk factors

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

Age

1.04

(1.02, 1.07)

 < 0.001

1.05

(1.02, 1.08)

0.004

1.10

(1.07, 1.14)

 < 0.001

1.05

(1.01, 1.09)

0.012

1.01

(0.99, 1.04)

0.376

—

  

Gender (male)

1.44

(0.87, 2.37)

0.156

—

  

1.62

(0.83, 3.14)

0.158

—

  

1.26

(0.71, 2.24)

0.433

—

  

Grade (G3 or 4)

0.90

(0.48, 1.67)

0.730

—

  

1.06

(0.49, 2.30)

0.888

—

  

1.06

(0.53, 2.12)

0.877

—

  

CEAa

1.46

(1.13, 1.87)

0.003

1.58

(1.10, 2.28)

0.014

1.61

(1.17, 2.20)

0.003

1.89

(1.26, 2.83)

0.002

1.54

(1.16, 2.04)

0.003

1.42

(0.81, 2.49)

0.215

LVI

2.06

(0.83, 5.14)

0.120

—

  

0.66

(0.09, 4.80)

0.680

—

  

2.21

(0.79, 6.14)

0.130

—

  

Node retrieval (< 12)

2.01

(1.22, 3.32)

0.006

1.74

(0.91,3.33)

0.093

1.78

(0.94, 3.40)

0.079

—

  

2.30

(1.26, 4.17)

0.006

1.63

(0.63, 4.23)

0.316

PNI

4.26

(1.70, 10.67)

0.002

3.31

(1.01, 10.89)

0.049

6.45

(2.27, 18.36)

 < 0.001

NAb

  

4.34

(1.56, 12.13)

0.005

7.33

(2.07, 25.95)

0.002

T stage (T2)

2.27

(1.09, 4.76)

0.029

1.05

(0.49, 2.22)

0.908

3.69

(1.14, 11.97)

0.030

1.05

(0.44, 2.47)

0.919

2.21

(0.94, 5.18)

0.070

—

  
  1. CEA Carcinoma embryonic antigen, LVI Lymphovascular invasion, PNI Perineural invasion, NA Not available
  2. aCEA levels were log-transformed
  3. bEffects could not be estimated due to scarce events in the risk group